Just thinking out loud…
My understanding is that we (inclusive of all co- owners of MSB & not to be confused with the royal ‘WE’) are seeking approval to have Remestemcel-L made available on market for paediatric sr aGVHD. Should such approval be given by the fda, we would not be competing with Jakafi as it has already failed in those patients we would be treating.
Once the adult trial is concluded & should approval be given, would we then be competing for the entire market (adult & paediatric) & from what stage of the disease would our treatment be used?
I’m asking also because I am keen to determine the treatment side effects & whether side effects are the same for the entire market or just adults?
Also, do physicians take into account side effects when choosing treatments & are patients informed?
https://hcp.jakafi.com/acute-graft-versus-host-disease/
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial, page-234
-
- There are more pages in this discussion • 129 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |